FDA Grants Orphan Drug Designation for Lundbeck's Cushing's Syndrome Drug Candidate

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Lundbeck's investigational anti-ACTH monoclonal antibody, asedebart. The drug, formerly identified as Lu AG13909, is designed to target adrenocorticotropic hormone (ACTH) for the potential treatment of endogenous Cushing's syndrome.

Endogenous Cushing's syndrome is a rare endocrine disorder typically caused by excess ACTH production, leading to chronic cortisol excess. This condition imposes a substantial disease burden, and current treatment options are often limited by suboptimal control and treatment-related complications.

Orphan Drug Designation is intended to encourage the development of treatments for rare diseases and may provide certain incentives, such as market exclusivity upon approval.

Lundbeck is currently conducting an ongoing proof-of-concept trial to evaluate the efficacy and safety of asedebart.